Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND AIMS Gamma-glutamyltransferase (GGT) is a serum marker of cholestasis. We investigated whether serum level of GGT is a prognostic marker for patients with primary biliary cholangitis (PBC). METHODS We analyzed data from patients with PBC from the Global PBC Study Group, comprising 14 centers in Europe and North America. We obtained measurements of serum GGT at baseline and time points after treatment. We used Cox model hazard ratios to evaluate the association between GGT and clinical outcomes, including liver transplantation and liver-related death. RESULTS Of the 2129 patients included in our analysis, 281 (13%) had a liver-related clinical endpoint. Mean age at diagnosis was 53 years and 91% of patients were female patients. We found a correlation between serum levels of GGT and alkaline phosphatase (ALP) (r=0.71). Based on data collected at baseline and yearly for up to 5 years, higher serum level of GGT were associated with lower hazard for transplant-free survival. Serum level of GGT at 12 months after treatment higher than 3.2-fold the upper limit of normal (ULN) identified patients who required liver transplantation or with liver-related death at 10 years with an area under the receiver operating characteristic curve of 0.70. The risk of liver transplantation or liver-related death in patients with serum level of GGT above 3.2-fold the ULN, despite level of ALP lower than 1.5-fold the ULN, was higher compared to patients with level of GGT lower than 3.2-fold the ULN and level of ALP lower than 1.5-fold the ULN (P<.05). Including information on level of GGT increased the prognostic value of the Globe score. CONCLUSION Serum level of GGT can be used to identify patients with PBC at risk for liver transplantation or death, and increase the prognostic value of ALP measurement. Our findings support the use of GGT as primary clinical endpoint in clinical trials. In patients with low serum level of ALP, a high level of GGT identifies those who might require treatment of metabolic disorders or treatment escalation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magnesium in man: implications for health and disease
de Baaij, J. H. F., Hoenderop, J. G. J., & Bindels, R. J. M. (2015) · Physiological Reviews · doi:10.1152/physrev.00012.2014 · Cited by 1,726
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
Self-citationA Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
Corpechot, C., Chazouillères, O., Rousseau, A., Le Gruyer, A., Habersetzer, F., Mathurin, P., Goria, O., Potier, P., Minello, A., Silvain, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714519 · Cited by 642
Self-citationLammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Self-citationLammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citationCarbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386
Self-citationCarbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354
Self-citationDeneau, M. R., El‐Matary, W., Valentino, P. L., Abdou, R., Alqoaer, K., Amin, M., Amir, A. Z., Auth, M., Bazerbachi, F., Broderick, A., et al. (2017) · Hepatology · doi:10.1002/hep.29204 · Cited by 230
Carbone, M., Nardi, A., Flack, S., Carpino, G., Varvaropoulou, N., Gavrila, C., Spicer, A., Badrock, J., Bernuzzi, F., Cardinale, V., et al. (2018) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(18)30163-8 · Cited by 155
Self-citationOhara, K., Masuda, T., Murakami, T., Imai, T., Yoshizawa, H., Nakagawa, S., Okada, M., Miki, A., Myoga, A., Sugase, T., et al. (2019) · Nephrology · doi:10.1111/nep.13552 · Cited by 81
Cited by
Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925
“2 fold the upper limit of normal (ULN) at 12 months after treatment identifies patients at increased risk of liver transplantation or liver-related death independently of ALP values [215].”
BackgroundSelf-citationPrimary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000395 · Cited by 127
Self-citationCorpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000529 · Cited by 94
Self-citationInvernizzi, P., Carbone, M., Jones, D., Levy, C., Little, N., Wiesel, P., Nevens, F., & the study investigators (2023) · Liver International · doi:10.1111/liv.15596 · Cited by 79
Self-citation
Metadata
- Authors
- Gerussi, A., Bernasconi, D. P., O'Donnell, S. E., Lammers, W. J., Van Buuren, H., Hirschfield, G., Janssen, H., Corpechot, C., Reig, A., Pares, A., Battezzati, P. M., Zuin, M. G., Cazzagon, N., Floreani, A., Nevens, F., Gatselis, N., Dalekos, G., Mayo, M. J., Thorburn, D., Bruns, T., Mason, A. L., Verhelst, X., Kowdley, K., van der Meer, A., Niro, G. A., Beretta-Piccoli, B. T., Marzioni, M., Belli, L. S., Marra, F., Valsecchi, M. G., Lindor, K. D., Invernizzi, P., Hansen, B. E., & Carbone, M.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 19
- Issue
- 8
- Pages
- 1688-1697.e14
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W3048139705
- Cited by
- 62
- References
- 11
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.